Search Results for: Pharma: Other News to Note
-
Other News To Note
The contract, issued under the Russian Federation's "Pharma 2020" development initiative, provides matching funding over a period of about three years, which will be used to support preclinical and clinical studies...Early this year, Theravance's partner for Vibativ, Astellas Pharma Inc., of Tokyo, handed back full rights to the program. (See BioWorld Today, Dec. 1, 2009...The company plans to disclose a new ticker symbol in JanuaryBioWorld Today | Wednesday, November 28, 2012 -
European Launch Imminent After CHMP OK for Lixisenatide
Friday's positive news does not trigger any milestone payment from Sanofi to Copenhagen, Denmark-based Zealand, but it can still take in $215 million in development and commercial milestones, including $40 million for a depot formulation of Lyxumia...Its safety and tolerability profile appears similar to other members of its class, with transient nausea, vomiting and diarrhea among the most common side effects...Other safety issues, according to the EMA, including hypoglycemia when Lyxumia wasBy Cormac Sheridan | BioWorld International | Wednesday, November 21, 2012 -
European Launch Imminent After CHMP OK for Lixisenatide
Friday's positive news does not trigger any milestone payment from Sanofi to Copenhagen, Denmark-based Zealand, but it can still take in $215 million in development and commercial milestones, including $40 million for a depot formulation of Lyxumia...Its safety and tolerability profile appears similar to other members of its class, with transient nausea, vomiting and diarrhea among the most common side effects...Other safety issues, according to the EMA, including hypoglycemia when Lyxumia wasBy Cormac Sheridan | BioWorld Today | Monday, November 19, 2012 -
Other News To Note
AlphaCore Pharma Inc., of Ann Arbor, Mich., said it received orphan designation from the European Medicines Agency for ACP-501 for familial LCAT deficiency (FLD), a rare, inherited condition that causes lipid accumulation in the eyes, red blood cells and kidneysBioWorld Today | Monday, November 5, 2012 -
Other News To Note
In other news, Cellectis said it signed two exclusive license agreements with Iowa State University granting the firm worldwide rights to inventions related to TAL effector-nucleases (TALENs) and monomeric TALENs...Pharma Two B Ltd., of Rehovot, Israel, completed a second round of financing for $8 million to develop its fixed-dose-combination product, P2B001, for Parkinson's disease and to complete a Phase IIb trialBioWorld International | Wednesday, October 31, 2012 -
Pharma: Other News To Note
Ltd., also of Osaka, said the European Medicines Agency confirmed the acceptance for review of the marketing application for atypical antipsychotic medication lurasidone, an oral, once-daily drug, for treating schizophrenia...The filing triggered a $5 million milestone payment to SoseiBioWorld Today | Friday, October 26, 2012 -
Other News To Note
BioAlliance Pharma SA, of Paris, said it signed a deal with Shafayab Gostar to distribute Loramyc (miconazole Lauriad mucoadhesive buccal tablet) in Iran for the treatment of oropharygeal candidiasis in immunocompromised patients...for turoctocog alfa, a third-generation recombinant coagulation Factor VIII intended for prevention and treatment of bleeding with people with hemophilia A. In other news, Novo Nordisk said the European Committee for Medicinal Products for Human Use adopted a positiveBioWorld International | Wednesday, October 24, 2012 -
Pharma: Other News To Note
Astellas Pharma Inc., of Tokyo, said the European Committee for Medicinal Products for Human Use adopted a positive opinion recommending approval of Betmiga (mirabegron) for the symptomatic treatment of urgency, increased micturition frequency and/or urgency incontinence as may occur in adults with overactive bladder syndrome...The hexavalent vaccine, aimed at protecting infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and invasive infections caused by HaemophilusBioWorld Today | Monday, October 22, 2012 -
Other News To Note
In other news, Almirall reported data from the MOVE 2 study supporting the use of Sativex, an endocannabinoid modulator, to reduce symptoms of moderate to severe spasticity due to multiple sclerosisBioWorld International | Wednesday, October 17, 2012 -
Other News To Note
AcelRx Pharmaceuticals Inc., of Redwood City, Calif., said the European Medicines Agency (EMA) agreed to permit registration of the Sufentanil NanoTab PCA System (ARX-01) via its centralized review process, enabling AcelRx to submit a single marketing authorization application for ARX-01 in all 27 European Union member states and four European Free Trade Association countries through a single evaluation by the Committee for Medicinal Products for Human Use...LEO Pharma A/S, of Ballerup, DenmarkBioWorld Today | Thursday, October 4, 2012 -
Other News To Note
In other news, Ablynx said it and partner Merck Serono, a division of Darmstadt, Germany-based Merck KGgA, advanced Nanobody candidate ALX-0751 into preclinical development in cancer...In other news, Boehringer and Eli Lilly and Co., of Indianapolis, said they received a positive opinion from the European Committee for Medicinal Products for Human Use for DPP-4 inhibitor Trajenta (linagliptin) in combination with insulin in adults with Type II diabetes...are soliciting consents from note holders forBioWorld International | Wednesday, September 26, 2012 -
Pharma: Other News To Note
Boehringer Ingelheim GmbH, of Ingelheim, Germany, said it submitted a marketing authorization application to the European Medicines Agency for approval of afatinib, an irreversible ErbB family blocker, as a treatment for patients with EGFR mutation-positive non-small-cell lung cancer...Lundbeck A/S, of Copenhagen, Denmark, said it submitted a marketing authorization application to the European Medicines Agency seeking approval of multimodal antidepressant vortioxetine (lu AA21004BioWorld Today | Friday, September 21, 2012 -
Other News To Note
The transaction now returns more cash to Nabi stockholders and provides increased certainty, through the use of a collar mechanism to protect against drops in the price of Biota shares...United Therapeutics Corp., of Silver Spring, Md., said under an exclusive agreement with Ascendis Pharma A/S, of Copenhagen, Denmark, it will apply Ascendis' TransCon technology platform to its treprostinil molecule, the active ingredient in Remodulin (treprostinil) injection for the treatment of pulmonary arterialBioWorld Today | Friday, September 21, 2012 -
Pharma: Other News To Note
Merck KGgA, of Darmstadt, Germany, said it withdrew its application from the European Medicines Agency seeking to extend the use of cancer drug Erbitux (cetuximab) in non-small-cell lung cancerBioWorld Today | Thursday, September 20, 2012 -
Other News To Note
In other news, BioLineRx said BL-7010, an oral candidate in celiac disease and gluten sensitivity, was found to be safe and well tolerated in preclinical studies presented at the Better Life for Coeliacs 2012 Conference in Helsinki, Finland...The company expects to submit a new drug application in PsA to the FDA in the first quarter of 2013 and a combined marketing authorization application in PsA and moderate-to-severe psoriasis to the European Medicines Agency in the second half of 2013BioWorld International | Wednesday, September 12, 2012 -
Other News To Note
Biogen Idec Inc., of Weston, Mass., sold royalty and other undisclosed rights to Benlysta (belimumab) to a fund managed by DRI Capital, of Toronto...Cardiome Pharma Corp., of Vancouver, British Columbia, said the European Society of Cardiology updated guidelines for the treatment of adult patients with recent onset atrial fibrillation that include the intravenous formulation of Brinavess (vernakalant) and other treatments, when pharmacologic cardioversion is preferred, as first-line therapy for theBioWorld Today | Tuesday, September 11, 2012 -
Pharma: Other News To Note
Janssen-Cilag International NV, of Beerse, Belgium, a unit of Johnson & Johnson, submitted a marketing authorization application to the European Medicines Agency seeking conditional approval for the use of TMC207 (bedaquiline) as part of combination therapy for pulmonary, multidrug-resistant tuberculosis (MDR-TB...Two months ago, Janssen submitted a new drug application for bedaquiline, under priority review, to the FDABioWorld Today | Tuesday, September 4, 2012 -
Other News To Note
Ariad Pharmaceuticals Inc., of Cambridge, Mass., said it submitted a marketing authorization application for ponatinib, its BCR-ABL inhibitor, to the European Medicines Agency to treat adults with resistant or intolerant chronic myeloid leukemia (CML) and Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ALL...Piper Jaffray analyst Edward A. Tenthoff said in a research note that the news is "a likely positive" and he continues to expect Cabo approval by the PDUFA dateBioWorld Today | Friday, August 31, 2012 -
Other News To Note
Astellas Pharma Inc., of Tokyo, disclosed plans to close subsidiary Urogenix Inc., of Durham, N.C., a research facility focused on urology drug discovery that was acquired in 2006 from Dynogen Pharmaceuticals Inc...In other news, GSK said it submitted applications in the European Union and the U.S...In other news, Pluristem said the life of a patient, a 54-year-old woman diagnosed with lymphoma cancer, suffering from bone marrow failure has been saved using Placental eXpanded (PLX) cellsBioWorld International | Wednesday, August 8, 2012 -
Other News To Note
In other news, Almirall and Quintiles Transnational Corp., of Durham, N.C., entered a long-term strategic partnership to promote Almirall's respiratory portfolio in the UK, strengthening the companies' existing relationship...In other news, Eisai published results from a pivotal Phase III study (Study 304) of Fycompa (perampanel), for partial-onset seizures, in subjects 12 and older showing that once-daily perampanel 8 mg or 12 mg improved seizure control, and that both doses were safe and wellBioWorld International | Wednesday, August 1, 2012
Category
Current Filters
- xMedicines Agency
Related Keywords
Categories
- x BioWorld Today (219)
- x BioWorld International (112)
- x BioWorld Insight (1)
- x Bio Perspectives (1)
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.